IRIS
ANDREONI, MASSIMO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 83.600
AS - Asia 12.515
EU - Europa 10.857
SA - Sud America 1.831
Continente sconosciuto - Info sul continente non disponibili 1.475
AF - Africa 274
OC - Oceania 53
Totale 110.605
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 83.103
SG - Singapore 5.505
IT - Italia 2.406
CN - Cina 2.212
BR - Brasile 1.508
RU - Federazione Russa 1.432
DE - Germania 1.405
HK - Hong Kong 1.128
UA - Ucraina 1.036
IE - Irlanda 1.035
KR - Corea 943
VN - Vietnam 910
SE - Svezia 720
FR - Francia 697
BD - Bangladesh 642
GB - Regno Unito 597
FI - Finlandia 490
PL - Polonia 341
JP - Giappone 304
CA - Canada 273
IN - India 217
NL - Olanda 177
MX - Messico 107
ZA - Sudafrica 106
AR - Argentina 105
ID - Indonesia 98
AT - Austria 97
TR - Turchia 92
BE - Belgio 88
ES - Italia 80
IQ - Iraq 75
CZ - Repubblica Ceca 65
PK - Pakistan 51
AU - Australia 49
EC - Ecuador 48
CO - Colombia 46
PH - Filippine 44
CL - Cile 39
VE - Venezuela 36
JM - Giamaica 31
KG - Kirghizistan 31
MA - Marocco 31
SA - Arabia Saudita 27
UZ - Uzbekistan 25
CH - Svizzera 24
AE - Emirati Arabi Uniti 23
JO - Giordania 23
EU - Europa 21
IR - Iran 21
LT - Lituania 21
TN - Tunisia 20
CR - Costa Rica 19
IL - Israele 19
MY - Malesia 19
PY - Paraguay 19
GR - Grecia 18
KE - Kenya 18
RO - Romania 18
EG - Egitto 17
KZ - Kazakistan 15
DZ - Algeria 14
TW - Taiwan 14
NP - Nepal 13
PE - Perù 13
AL - Albania 12
ET - Etiopia 12
CM - Camerun 11
HR - Croazia 10
PT - Portogallo 10
TH - Thailandia 10
DK - Danimarca 9
HN - Honduras 9
SI - Slovenia 9
TT - Trinidad e Tobago 9
UY - Uruguay 9
A2 - ???statistics.table.value.countryCode.A2??? 8
OM - Oman 8
AZ - Azerbaigian 7
BA - Bosnia-Erzegovina 7
NO - Norvegia 7
PR - Porto Rico 7
SC - Seychelles 7
AO - Angola 6
BG - Bulgaria 6
BH - Bahrain 6
HU - Ungheria 6
LV - Lettonia 6
NG - Nigeria 6
PA - Panama 6
RS - Serbia 6
BO - Bolivia 5
DO - Repubblica Dominicana 5
GT - Guatemala 5
LB - Libano 5
SV - El Salvador 5
BS - Bahamas 4
GH - Ghana 4
MK - Macedonia 4
NI - Nicaragua 4
NZ - Nuova Zelanda 4
Totale 109.075
Salva come PNG Salva come JPEG
Città #
Woodbridge 21.632
Wilmington 21.429
Houston 15.556
Singapore 3.216
Fairfield 2.567
Ashburn 1.981
Chandler 1.860
Ann Arbor 1.816
San Jose 1.561
Hong Kong 1.108
Seattle 1.087
Beijing 893
Dublin 871
Cambridge 870
Jacksonville 816
Council Bluffs 782
Rome 759
New York 682
Medford 650
Dearborn 568
Santa Clara 532
Los Angeles 479
The Dalles 466
Lawrence 304
Ho Chi Minh City 281
Tokyo 274
Helsinki 256
Kraków 254
Milan 233
Moscow 232
Buffalo 228
Hanoi 228
Dallas 224
Lauterbourg 211
San Diego 203
São Paulo 163
Munich 161
Menlo Park 158
Orem 145
Zhengzhou 127
Boardman 118
Nuremberg 117
London 111
Phoenix 105
Mülheim 97
Chicago 91
Brussels 87
North Bergen 86
Montreal 80
Redondo Beach 78
Toronto 75
Chennai 74
Atlanta 72
Frankfurt am Main 71
Jakarta 68
Denver 63
Warsaw 63
Brooklyn 60
Nanjing 59
Amsterdam 58
Johannesburg 57
Palo Alto 57
Naples 56
Guangzhou 51
San Francisco 51
Shanghai 51
Falls Church 50
Stockholm 49
Redwood City 48
Rio de Janeiro 48
Manchester 47
Verona 47
Norwalk 45
Dong Ket 43
Hefei 43
Hangzhou 42
Columbus 41
San Mateo 41
Poplar 38
Seoul 38
Belo Horizonte 37
Da Nang 37
Mountain View 37
Vienna 37
Brno 36
Boston 35
Mexico City 35
Ankara 32
Kunming 32
Baghdad 30
Bari 30
Haiphong 30
Creede 29
Curitiba 29
Salt Lake City 29
Lappeenranta 28
Mumbai 28
University Park 28
Charlotte 26
Paris 26
Totale 89.070
Salva come PNG Salva come JPEG
Nome #
Persistent risk of HBV reactivation despite extensive lamivudine prophylaxis in haematopoietic stem cell transplant recipients who are anti-HBc-positive or HBV-negative recipients with an anti-HBc-positive donor 587
HCV NS3 sequencing as a reliable and clinically useful tool for the assessment of genotype and resistance mutations for clinical samples with different HCV-RNA levels 580
Microbiologic characteristics and predictors of mortality in bloodstream infections in intensive care unit patients: A 1-year, large, prospective surveillance study in 5 Italian hospitals 544
The Genotypic False Positive Rate Determined by Population V3-Sequencing can Predict the Burden of X4 Quasispecies Detected by Pyrosequencing 535
18-Fluoro-2-deoxyglucose positron emission tomography-computed tomography: an additional tool in the diagnosis of prosthetic valve endocarditis. 526
Clinical predictors and microbiology of ventilator-associated pneumonia in the intensive care unit: a retrospective analysis in six Italian hospitals 524
The lowest X4 Geno2Pheno false-positive rate is associated with greater CD4 depletion in HIV-1 infected patients 517
Snapshot on drug-resistance rate and profiles in patients with chronic hepatitis B receiving nucleos(t)ide analogues in clinical practice 515
Human herpesvirus-8 infection in pregnancy and labor: Lack of evidence of vertical transmission 507
Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study 496
Hepatitis C virus RNA levels at week-2 of telaprevir/boceprevir administration are predictive of virological outcome 495
Novel HBsAg mutations correlate with hepatocellular carcinoma, hamper HBsAg secretion and promote cell proliferation in vitro 492
A stable CC-chemokine receptor (CCR)-5 tropic virus is correlated with the persistence of HIV RNA at less than 2.5 copies in successfully treated naïve subjects. 488
Hepatitis B surface antigen genetic elements critical for immune escape correlate with hepatitis B virus reactivation upon immunosuppression 487
Replication capacity, biological phenotype, and drug resistance of HIV strains isolated from patients failing antiretroviral therapy 486
Infection with human herpesvirus type 8 and Kaposi's sarcoma in a central Italian area formerly endemic for malaria 485
Viro-immunological response of drug-naive HIV-1-infected patients starting a first-line regimen with viraemia >500,000 copies/ml in clinical practice 484
Prognostic factors of long-term CD4+ count-guided interruption of antiretroviral treatment 482
Specific mutations in the C-terminus domain of HBV surface antigen significantly correlate with low level of serum HBV-DNA in patients with chronic HBV infection 480
Comparative evaluation of subtyping tools for the surveillance of newly emerging HIV-1 strains 479
Cellular HIV-1 DNA quantitation in patients during simplification therapy with protease inhibitor-sparing regimens 478
Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies 478
Successful switch to tenofovir after suboptimal response to entecavir in an immunocompromised patient with chronic hepatitis B and without genotypic hepatitis B virus resistance. 473
Optimal efficacy of interferon-free HCV retreatment after protease inhibitors failure in real life. 470
HIV-1 residual viremia and proviral DNA in patients with suppressed plasma viral load (< 400 HIV-RNA cp/ml) during different antiretroviral regimens 468
A fatal case of invasive fungal sinusitis by Scopulariopsis acremonium in a bone marrow transplant recipient 467
Efficient and reproducible new semimicromethod for the detection and titration of HIV in human plasma 467
Drug-associated resistance mutations in plasma and peripheral blood mononuclear cells of human immunodeficiency virus type 1-infected patients for whom highly active antiretroviral therapy is failing 466
HCV genotypes are differently prone to the development of resistance to linear and macrocyclic protease inhibitors 466
Multidrug resistance after lamivudine therapy for chronic hepatitis B 466
Novel HBsAg markers tightly correlate with occult HBV infection and strongly affect HBsAg detection. 465
HIV plasma viremia in 22 seropositive subjects [VALUTAZIONE DELLA VIREMIA PLASMATICA DA HIV IN 22 SOGGETTI SIERO-POSITIVI] 463
Dysplasia of Granulocytes in a Patient with HPV Disease, Recurrent Infections, and B Lymphopenia: A Novel Variant of WHIM Syndrome? 463
Correlation between changes in plasma HIV RNA levels and in plasma infectivity in response to antiretroviral therapy. 455
Decrease of replicative capacity of HIV isolates after genotypic guided change of therapy 454
Specific HbsAg genetic determinants are associated with occult HBV infection in vivo and HbsAg detection 454
Clinical outcome after 4 years follow-up of HIV-seropositive subjects with incomplete virologic or immunologic response to HAART 452
Specific HBSAG Genetic- Determinants are associated with occult HBV-infection in vivo and HBSAG detection 450
Neutralizing antibodies against autologous human immunodeficiency virus type 1 isolates in patients with increasing CD4 cell counts despite incomplete virus suppression during antiretroviral treatment 448
Identification and structural characterization of novel genetic elements in the HIV-1 V3 loop regulating coreceptor usage 448
Association between cellular human immunodeficiency virus DNA level and immunological parameters in patients with undetectable plasma viremia level during highly active antiretroviral therapy 447
Reduction of IFN-gamma and IL-2 production by peripheral lymphocytes of HIV-exposed seronegative subjects 446
A case of rhabdomiolysis associated with raltegravir use 446
High seroprevalence of antibodies to human herpesvirus-8 in Egyptian children: evidence of nonsexual transmission. 446
HIV-1 dual/mixed tropic isolates show different genetic and phenotypic characteristics and response to maraviroc in vitro 446
Cortical sources of resting state electroencephalographic rhythms probe brain function in naïve HIV individuals 446
Failure of stavudine-lamivudine combination therapy in antiretroviral-naive patients with AZT-like HIV-1 resistance mutations 445
High prevalence of M184 mutation among patients with viroimmunologic discordant responses to highly active antiretroviral therapy and outcomes after change of therapy guided by genotypic analysis 445
Anti-HBV treatment induces novel reverse transcriptase mutations with reflective effect on HBV S antigen 445
HIV phenotype switching during antiretroviral therapy: emergence of saquinavir-resistant strains with less cytopathogenicity 444
Raltegravir plasma concentrations in treatment-experienced patients receiving salvage regimens based on raltegravir with and without maraviroc coadministration 441
A very low geno2pheno false positive rate is associated with poor viro-immunological response in drug-naïve patients starting a first-line HAART. 441
Human herpesvirus 8 and human herpesvirus 2 infections in prison population 439
ellular proviral HIV-DNA decline and viral isolation in naïve subjects with <5000 copies/ml of HIV-RNA and >500 x 10(6)/l CD4 cells treated with highly active antiretroviral therapy. 439
Viral growth assay to evaluate the replicative capacity of HIV-1 isolates 437
Performance of genotypic tropism testing on proviral DNA in clinical practice: results from the DIVA Study Group 436
Characterization of drug resistance mutations in naive and ART-treated patients infected with HIV-1 in Yaounde, Cameroon 435
Performance of genotypic tropism testing in clinical practice using the enhanced sensitivity version of Trofile as reference assay: results from the OSCAR Study Group 434
Dapsone hypersensitivity syndrome complicated by Scedosporium apiospermum pneumonia in an immunocompetent patient. 434
Drug resistance in B and non-B subtypes amongst subjects recently diagnosed as primary/recent or chronic HIV-infected over the period 2013-2016: impact on susceptibility to first-line strategies including Integrase strand-transfer inhibitors 434
Key patterns of HBX and pre-S1/S2 mutations are involved in mechanisms underlying HBV-induced hepatocellular carcinoma in vivo 433
Correlates of HIV, HBV, and HCV infections in a prison inmate population: Results from a multicentre study in Italy 432
Increase in neutralizing antibody titer against sequential autologous HIV-1 isolates after 16 weeks saquinavir (invirase) treatment 432
Successful switch to tenofovir after suboptimal response to entecavir in an immunocompromised patient with chronic hepatitis B and without genotypic hepatitis B virus resistance 432
Five human immunodeficiency virus type 1 phenotypic variants with different MT-2 cell tropisms correlate with prognostic markers of disease 432
Complication of nasal piercing by Staphylococcus aureus endocarditis: a case report and a review of literature. 431
Adherence and genotypic drug resistance mutations in HIV-1-infected patients failing current antiretroviral therapy 431
Infection with human herpesvirus-8 and its correlation with hepatitis B virus and hepatitis C virus markers among rural populations in Cambodia 429
Interleukin-15 production by monocyte-derived dendritic cells and T cell proliferation in HIV-infected patients with discordant response to highly active antiretroviral therapy 429
Prevalence of HHV-8 infection in Albanian adults and association with HBV and HCV 428
Late hepatitis B virus reactivation after lamivudine prophylaxis interruption in an anti-HBs-positive and anti-HBc-negative patient treated with rituximab-containing therapy 427
Plasma Viremia Titration and RNA Quantitation in ICD-p24 Negative HIV Type-1-Infected Patients 427
Virological response and resistance profile in HIV-1-infected patients starting darunavir-containing regimens 426
Optimal cure rate by personalized HCV regimens in real-life: a proof-of-concept study 425
Ultrasensitive assessment of residual HIV viraemia in HAART-treated patients with persistently undetectable plasma HIV-RNA: A cross-sectional evaluation 423
Genotypic testing on HIV-1 DNA as a tool to assess HIV-1 co-receptor usage in clinical practice: results from the DIVA study group 423
Prevalence and risk factors for human herpesvirus 8 infection in northern Cameroon 423
An update on integrase inhibitors: new opportunities for a personalized therapy? The NEXTaim Project 423
Genotypic resistance test in proviral DNA can identify resistance mutations never detected in historical genotypic test in patients with low level or undetectable HIV-RNA 423
HBV, HCV, HDV AND HEV COINFECTIONS IN A COHORT OF HIV POSITIVE PATIENTS IN CAMEROON 422
Inhibition of dual/mixed tropic HIV-1 isolates by CCR5-inhibitors in primary lymphocytes and macrophages 422
HIV neutralizing antibody titer during structured treatment interruption of highly active antiretroviral therapy 421
KSHV DNA viremia correlates with low CD4+ cell count in Italian males at the time of diagnosis of HIV infection 420
Secondary integrase resistance mutations found in HIV-1 minority quasispecies in integrase therapy-naive patients have little or no effect on susceptibility to integrase inhibitors 420
Virological response to salvage therapy in HIV-infected persons carrying the reverse transcriptase K65R mutation 419
Improvement of ALT decay kinetics by all-oral HCV treatment: Role of NS5A inhibitors and differences with IFN-based regimens 419
Prevalence trend and correlates of HHV-8 infection in HIV-infected patients 418
Once-a-day (QD) vs. Twice-daily (BID) Nevirapine as Simplification in PI-Treated Patients after 2 mos. of BID Induction 418
Saquinavir/zidovudine combination in patients with advanced HIV infection and no prior antiretroviral therapy: CD4+ lymphocyte/plasma RNA changes, and emergence of HIV strains with reduced phenotypic sensitivity. 418
Primary human herpesvirus 8 infection in immunocompetent children. 418
Human herpesvirus 8 cytoviraemia rebound in a patient with Kaposi's sarcoma after a short interruption of efficient antiretroviral therapy. 418
Biomarkers of monitoring and functional reserve of physiological systems over time in HIV: expert opinions for effective secondary prevention 416
Infection with human herpesvirus type 8 and human T-cell leukaemia virus type 1 among individuals participating in a case-control study in Havana City, Cuba 415
High Burden of HBV-Infection and Atypical HBV Strains among HIV-infected Cameroonians 411
Dual mixed (but not X4) tropic-HIV-1 isolates can replicate in human primary macrophages and are inhibited by CCR5- inhibitors 411
Time course of cellular HIV-DNA and low-level HIV viremia in HIV–HCV co-infected patients whose HCV infection had been successfully treated with directly acting antivirals 409
Access and response to direct antiviral agents (DAA) in HIV-HCV co-infected patients in Italy: Data from the Icona cohort 408
Non-B HIV type 1 subtypes: Replicative capacity and response to antiretroviral therapy 407
High rate of HIV isolation from plasma of asymptomatic patients through polyethylene glycol (PEG) treatment 407
Impact of pre-therapy viral load on virological response to modern first-line HAART 406
Totale 45.118
Salva come PNG Salva come JPEG
Categoria #
all - tutte 296.085
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 296.085
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20223.486 0 0 229 271 171 448 223 213 466 307 243 915
2022/20234.898 479 400 301 641 413 1.043 371 348 460 36 270 136
2023/20242.072 261 75 158 110 162 446 102 148 54 144 28 384
2024/20259.077 321 1.861 918 646 277 584 878 551 918 907 643 573
2025/202615.627 1.195 648 1.597 1.399 1.469 676 2.111 1.823 1.917 1.289 829 674
2026/20271.926 1.033 839 54 0 0 0 0 0 0 0 0 0
Totale 110.605